A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response
- Nat Commun. 2026 May 6. doi: 10.1038/s41467-026-72688-y.
- 1. Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. [email protected].
- 2. Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
- 3. Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK.
- 4. X-Chem Inc., Waltham, Massachusetts, USA.
- 5. Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
- 6. Neuroscience, R&D, AstraZeneca, Cambridge, UK.
- 7. Department of Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- 8. Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
- # Contributed equally.
Eukaryotic initiation factor 2B (eIF2B), a guanine nucleotide exchange factor (GEF), promotes protein synthesis by charging translation initiation factor 2 (eIF2) with GTP. Stress-induced phosphorylation of eIF2 on its α-subunit [eIF2(αP)] inhibits this reaction triggering a protective Integrated Stress Response (ISR). A DNA-encoded chemical library (DEL) screen for modulators of eIF2B, led to the identification of a chemical series that stabilises the inactive state of eIF2B, stimulating the ISR. Cryo-EM of compound-bound eIF2B reveals a conformational switch to the inactive state engaged by eIF2(αP). In cells, compound activity is sensitive to eIF2's phosphorylation state and to a competing eIF2B ligand (ISRIB) that activates the GEF allosterically. These findings establish the feasibility of targeting eIF2B with a drug-like allosteric inhibitor, that serves as an ISR activator (ISRAC), paving the way to explore the therapeutic potential of eIF2B-directed ISR activation.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-